Minerva Neurosciences, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Minerva Neurosciences, Inc. (NERV) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $4.17 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-07
- Minerva Neurosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $4.22, a 31.49% decline year-over-year.
- Minerva Neurosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $6.16, a 26.75% decline year-over-year.
- Minerva Neurosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $8.41, a 21.77% decline year-over-year.
- Minerva Neurosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $10.75, a 459.90% increase year-over-year.
- Minerva Neurosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $4.07, a 34.04% decline from fiscal 2024.
- Minerva Neurosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $6.17, a 25.75% decline from fiscal 2023.
- Minerva Neurosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $8.31, a 22.70% decline from fiscal 2022.
- Minerva Neurosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $10.75, a 278.52% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 0 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $4.17 10-Q · filed 2026-08-07 | ||||
| 2026-03-31 | $4.22 10-Q · filed 2026-05-05 | ||||
| 2025-12-31 | $4.07 10-K · filed 2026-03-11 | ||||
| 2025-09-30 | $6.20 10-Q · filed 2025-11-05 | ||||
| 2025-06-30 | $6.11 10-Q · filed 2026-08-07 | ||||
| 2025-03-31 | $6.16 10-Q · filed 2026-05-05 | ||||
| 2024-12-31 | $6.17 10-K · filed 2026-03-11 | ||||
| 2024-09-30 | $8.26 10-Q · filed 2024-11-05 | ||||
| 2024-06-30 | $8.25 10-Q · filed 2024-08-06 | ||||
| 2024-03-31 | $8.41 10-Q · filed 2024-05-01 | ||||
| 2023-12-31 | $8.31 10-K · filed 2024-02-22 | ||||
| 2023-09-30 | $9.88 10-Q · filed 2023-11-07 | ||||
| 2023-06-30 | $10.75 10-Q · filed 2023-08-01 | ||||
| 2023-03-31 | $10.75 10-Q · filed 2023-05-15 | ||||
| 2022-12-31 | $10.75 10-K · filed 2023-03-08 | ||||
| 2022-09-30 | $14.94 10-Q · filed 2022-11-09 | ||||
| 2022-06-30 | $14.94 10-Q · filed 2022-08-09 | ||||
| 2022-03-31 | $1.92 10-Q · filed 2022-05-04 | ||||
| 2021-12-31 | $2.84 10-K · filed 2022-03-01 | ||||
| 2021-09-30 | $3.13 10-Q · filed 2021-11-08 | ||||
| 2021-06-30 | $4.13 10-Q · filed 2021-08-02 | ||||
| 2021-03-31 | $4.14 10-Q · filed 2021-05-12 | ||||
| 2020-12-31 | $4.15 10-K · filed 2021-03-08 | ||||
| 2020-09-30 | $4.32 10-Q · filed 2020-11-02 | ||||
| 2020-06-30 | $4.36 10-Q · filed 2020-08-03 | ||||
| 2020-03-31 | $5.01 10-Q · filed 2020-05-04 | ||||
| 2019-12-31 | $5.04 10-K · filed 2020-03-09 | ||||
| 2019-09-30 | $5.08 10-Q · filed 2019-11-04 | ||||
| 2019-06-30 | $5.14 10-Q · filed 2019-08-05 | ||||
| 2019-03-31 | $5.17 10-Q · filed 2019-05-06 | ||||
| 2018-12-31 | $5.18 10-K · filed 2019-03-12 | ||||
| 2018-09-30 | $4.99 10-Q · filed 2018-11-05 | ||||
| 2018-06-30 | $4.95 10-Q · filed 2018-08-02 | ||||
| 2018-03-31 | $4.95 10-Q · filed 2018-05-03 | ||||
| 2017-12-31 | $4.98 10-K · filed 2018-03-12 | ||||
| 2017-09-30 | $5.08 10-Q · filed 2017-11-06 | ||||
| 2017-06-30 | $6.53 10-Q · filed 2017-08-03 | ||||
| 2017-03-31 | $5.19 10-Q · filed 2017-05-04 | ||||
| 2016-12-31 | $5.13 10-K · filed 2017-03-13 | ||||
| 2016-09-30 | $5.53 10-Q · filed 2017-11-06 | ||||
| 2016-06-30 | $5.53 10-Q · filed 2017-08-03 | ||||
| 2015-12-31 | $3.83 10-K · filed 2016-03-14 | ||||
| 2015-09-30 | $4.26 10-Q · filed 2016-11-03 | ||||
| 2015-06-30 | $4.21 10-Q · filed 2016-08-04 | ||||
| 2015-03-31 | $3.68 10-Q · filed 2016-05-03 | ||||
| 2015-02-02 | $2.72 10-Q · filed 2015-05-07 | ||||
| 2015-01-02 | $5.13 10-Q · filed 2015-05-07 | ||||
| 2014-12-31 | $5.81 10-K · filed 2016-03-14 | ||||
| 2014-09-30 | $5.81 10-Q · filed 2015-11-05 | ||||
| 2014-06-30 | $5.11 10-Q · filed 2015-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |